Pharmacokinetic, Pharmacodynamic Profiles and Safety After Oral Administration of Ivabradine in Male Healthy Korean Volunteers

Asan Medical Center48 enrolled

Overview

1. To assess the pharmacokinetic profile of ivabradine (S 16257) and its main active metabolite S 18982 in Korean healthy volunteers after oral administration of ivabradine at the doses of 2.5, 5, 10mg and after repeated oral administrations of ivabradine for 4.5 days at the same doses twice daily versus placebo and to use the study results for bridging with Caucasian data. 2. The pharmacodynamic profile of ivabradine versus placebo by measuring its effects on heart rate after single and then after repeated administrations. 3. Clinical safety of ivabradine versus placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Healthy Individual

Interventions

Ivabradine and placebo

Eligibility

Sex: MALEMin age: 18 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * age between 18 and 40 years and Korean * Nonsmoker or smoke less than 5 cigarettes per day * normal dietary habits * BMI ranging from 18 to 25 kg/m2 * good physical and mental status, determined by the investigator * vital signs in resting condition within range: SBP 100-139 mmHg, DBP 50-89 mmHg * Normal ECG Exclusion Criteria: * Participate any other trial in the last 3 months prior to the study * History of major psychiatric, medical, surgical disorders * Acute, or chronic disease * History of hypersensitivity to at least one drug * History of alcoholism or positive alcohol breath test * Positive drug screening results * known positive serology for HIV1, HIV2, hepatitis B or C * blood donor within the last 3 month of the study * regular use of sedatives, hypnotics, tranquillisers

Outcomes

Primary Outcomes

Cmax,tmax, AUC(Area under the time-concentration curve) of ivabradine and metabolite

For PK measurements, blood samplings were done: pre-dose then 20 min, 40 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 36 h, 48 h, 60 h, and 72 h following the D1 single administration (P1) and the Day 8 (D8) last repeated dose (P2), respectively.Ivabradine and its main metabolite were determined using LC-MS/MS, then pharmacokinetic parameters were calculated by noncompartmental approach. Descriptive statistics were performed on the PK individual parameters calculated from the plasma concentration-time profiles.

Time frame: within 60 days after blood sampling (blood sample analysis)

Secondary Outcomes

pharmacodynamics: The change of heart rate between baseline and over 24-hour, diurnal, nocturnal, awake, and asleep periods after administration of ivabradine

For PD measurements, 24-hour Holter recordings were performed on Day0, Day1, Day8, and Day10. a resting 12-lead ECG were also performed. The changes of heart rate between day 1 and baseline values, between day 8 and baseline values were studied over 24-hour, diurnal, nocturnal, awake and asleep period for each ivabradine dose in comparison with placebo. Descriptive statistics by dose were performed and confidence intervals of the differences between each dose of ivabradine and placebo were constructed using a non-parametric method based on Hodges \& Lehman estimate for independent samples.

Time frame: within 10 days after administration